In a randomized crossover experiment of 15 people with T1D, each participant experienced two therapy phases: a closed-loop system for glucose management, during which liraglutide (1.2 mg daily) and insulin were administered. The gene discussed is INS; the disease is type 1 diabetes mellitus.